RPG Life Sciences Limited (RPGLIFE) Fair Value & Analysis
Healthcare · IN · Market cap ₹39.6B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price +9.9% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,744 – ₹2,658 · fair‑value band ₹533.75 – ₹1,660 · the ₹2,416 price screens above the ₹762.51 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
RPG Life Sciences Limited (RPGLIFE) currently trades at ₹2,416, while our model-based Fair Value estimate is ₹762.51 — implying the stock looks roughly 68.4% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, RPG Life Sciences Limited generated revenue of ₹7.1B at a net margin of 16.3%. Revenue grew 23.6% year over year. It earns a return on equity of 20.3%. The balance sheet holds a net cash position of ₹1.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
RPG Life Sciences Limited reported revenue of ₹7.1B in FY2026 versus ₹4.4B in FY2022, a compound +12.8%/yr. Reported net income was ₹1.2B in FY2026, compounding +22.3%/yr from FY2022.
Is RPGLIFE fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is RPG Life Sciences Limited (RPGLIFE) undervalued?
What is the fair value of RPGLIFE?
What is the quality score of RPGLIFE?
What is the revenue of RPG Life Sciences Limited (RPGLIFE)?
What is the net profit margin of RPGLIFE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.